%0 Journal Article
%T Signaling Crosstalk between PPAR¦Ă and BMP2 in Mesenchymal Stem Cells
%A Ichiro Takada
%A Yoshiko Yogiashi
%A Shigeaki Kato
%J PPAR Research
%D 2012
%I Hindawi Publishing Corporation
%R 10.1155/2012/607141
%X Recent studies have revealed that PPAR¦ĂˇŻs transactivation function is regulated by extracellular signals. In particular, cytokines and Wnt family proteins suppress the ligand-inducible transactivation function of PPAR¦Ă and attenuate adipogenesis/osteoblastogenesis switching in mesenchymal stem cells (MSCs). For example, Wnt5a suppresses PPAR¦Ă transcriptional activity through the NLK/SETDB1/CHD7 pathway. Among these factors, BMP2 strongly induces bone formation, but the effect of BMP2 on PPAR¦Ă function remains unclear. We examined the effect of BMP2 and PPAR¦Ă in ST2 cells and found that PPAR¦Ă activation affected BMP2ˇŻs signaling pathway through epigenetic regulation. Although BMP2 did not interfere with PPAR¦Ă-mediated adipogenesis, BMP2 increased mRNA expression levels of PPAR¦Ă target genes (such as Fabp4 and Nr1h3) when cells were first treated with troglitazone (TRO). Moreover, PPAR¦Ă activation affected BMP2 through enhancement of histone activation markers (acetylated histone H3 and trimethylated Lys4 of histone H3) on the Runx2 promoter. After TRO treatment for three hours, BMP2 enhanced the levels of active histone marks on the promoter of a PPAR¦Ă target gene. These results suggest that the order of treatment with BMP2 and a PPAR¦Ă ligand is critical for adipogenesis and osteoblastogenesis switching in MSCs. 1. Introduction Mesenchymal stem cells (MSCs) are useful tools for regeneration therapy because of the ease of their isolation from patients and straightforward handling in culture. MSCs are derived from various adult tissues (such as adipose tissue and bone marrow) and have the potential to differentiate into a variety of lineages, including osteoblasts, chondrocytes, adipocytes, and myocytes [1, 2]. Recent studies have identified differentiation regulators in MSCs. Among these factors, PPAR¦Ă is commonly accepted as the master adipogenic factor since activation of PPAR¦Ă in precursors of nonadipogenic lineage cells triggers their transdifferentiation into adipocytes [3, 4]. Endogenous and synthetic PPAR¦Ă agonists (15-deoxy-¦¤(12,14)-prostaglandin J2 and thiazolidinediones) promote adipogenesis and inhibit osteoblastogenesis in primary bone marrow MSC culture [5]. Moreover, treatment of mice with rosiglitazone (a thiazolidinedione) increases bone marrow adiposity and decreases bone mineral density (BMD, or bone mass) apparently through suppression of pro-osteoblastic transcription factors Runx2, Osterix, and Dlx5 [6, 7]. Haploinsufficiency of PPAR¦Ă in mice results in enhanced osteoblastogenesis and decreased bone marrow adipogenesis with increased
%U http://www.hindawi.com/journals/ppar/2012/607141/